Evaluation of serum levels of Interleukin-4 in Egyptian patients with refractory gastroesophageal reflux disease

References

• El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut. 2014;63(6):871–880.
   PubMed Web of Science ®Google Scholar
• Tack J, Becher A, Mulligan C, et al. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35(11):1257–1266.
   Web of Science ®Google Scholar
• Vakil N. A global evidence-based consensus definition and classification of gastroesophageal reflux disease. Ther Res. 2006;27(5):805–812.
   Google Scholar
• Bytzer P, Van Zanten SV, Mattsson H, et al. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - A post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36(7):635–643.
   Web of Science ®Google Scholar
• Cicala M, Emerenziani S, Guarino MPL, et al. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol. 2013;19(39):6529–6535.
   PubMed Web of Science ®Google Scholar
• Mermelstein J, Mermelstein AC, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018;11:119–134.
   PubMed Web of Science ®Google Scholar
• Isomoto H, Inoue K, Kohno S. Interleukin-8 levels in esophageal mucosa and long-term clinical outcome of patients with reflux esophagitis. Scand J Gastroenterol. 2007;42(3):410–411.
   PubMed Web of Science ®Google Scholar
• Kohata Y, Fujiwara Y, MacHida H, et al. Role of Th-2 cytokines in the development of Barrett’s esophagus in rats. J Gastroenterol. 2011;46(7):883–893.
   Web of Science ®Google Scholar
• Zhong YQ, Lin Y, Xu Z. Expression of IFN-γ and IL-4 in the esophageal mucosa of patients with reflux esophagitis and Barrett’s esophagus and their relationship with endoscopic and histologic grading. Dig Dis Sci. 2011;56(10):2865–2870.
   Web of Science ®Google Scholar
• Howard M, Farrar J, Hilfiker M, et al. Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J Exp Med. 1982;155(3):914–923.
   PubMed Web of Science ®Google Scholar
• Hu-Li J. B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes. J Exp Med. 2004;165(1):157–172.
   Google Scholar
• Hart PH, Vitti GF, Burgess DR, et al. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci U S A. 1989;86(10):3803–3807.
   PubMed Web of Science ®Google Scholar
• Major J, Fletcher JE, Hamilton TA. IL-4 pretreatment selectively enhances cytokine and chemokine production in lipopolysaccharide-stimulated mouse peritoneal macrophages. J Immunol. 2014;168(5):2456–2463.
   Google Scholar
• Fort MM, Lesley R, Davidson NJ, et al. IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J Immunol. 2014;166(4):2793–2800.
   Google Scholar
• Gadani SP, Cronk JC, Norris GT, et al. IL-4 in the Brain: A Cytokine To Remember. J Immunol. 2012;189(9):4213–4219.
   Web of Science ®Google Scholar
• Hershcovici T, Fass R. Step-by-step management of refractory gastresophageal reflux disease. Dis Esophagus. 2013;26(1):27–36.
   Web of Science ®Google Scholar
• Li J, Chen X, Shaker A, et al. Contribution of immunomodulators to gastroesophageal reflux disease and its complications: stromal cells, interleukin 4, and adiponection. Ann N Y Acad Sci. 2016;1380(1):183–194.
   Google Scholar
• Ivashkin V, Evsyutina Y, Trukhmanov A, et al. Systemic inflammatory response in patients with gastroesophageal reflux disease. Am J Clin Med Res. 2015;3(4):64–69.
   Google Scholar
• Westhoff B, Brotze S, Weston A, et al. The frequency of Barrett’s esophagus in high-risk patients with chronic GERD. Gastrointest Endosc. 2015;61(2):226–231.
   Google Scholar
• Gado A, Ebeid B, Abdelmohsen A, et al. Prevalence of reflux esophagitis among patients undergoing endoscopy in a secondary referral hospital in Giza, Egypt. Alexandria J Med. 2015;51:89–94.
   Web of Science ®Google Scholar
• Piqué N, Ponce M, Garrigues V, et al. Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study). United European Gastroenterol J. 2016;4(2):229–235.
   Web of Science ®Google Scholar
• Loke SS, Kuender D, Yang KD, et al. Erosive esophagitis associated with metabolic syndrome, impaired liver function, and dyslipidemia. World J Gastroenterol. 2013;19(35):5883–5888.
   Web of Science ®Google Scholar